Effect of Abciximab on the Levels of Circulating Microparticles in Patients with Acute Myocardial Infarction Treated by Primary Angioplasty.
10.4070/kcj.2013.43.9.600
- Author:
Jung Joon CHA
1
;
Jong Youn KIM
;
Eui Young CHOI
;
Pil Ki MIN
;
Minhee CHO
;
Da Lyung LEE
;
Sung Yu HONG
;
Young Won YOON
;
Byoung Kwon LEE
;
Bum Kee HONG
;
Se Joong RIM
;
Hyuck Moon KWON
Author Information
1. Cardiology Division, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. cardioblues@yuhs.ac
- Publication Type:Original Article
- Keywords:
Cell-derived microparticles;
Myocardial infarction;
Platelet aggregation inhibitors
- MeSH:
Angioplasty;
Annexin A5;
Antibodies, Monoclonal;
Cell-Derived Microparticles;
Femoral Artery;
Humans;
Immunoglobulin Fab Fragments;
Male;
Myocardial Infarction;
Percutaneous Coronary Intervention;
Platelet Aggregation Inhibitors
- From:Korean Circulation Journal
2013;43(9):600-606
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: We investigated the effect of the additional use of abciximab during percutaneous coronary intervention (PCI) on the level of procoagulant microparticles (MPs) in patients with ST-segment elevation myocardial infarction (STEMI) who had undergone primary PCI. SUBJECTS AND METHODS: In this study, we studied 86 patients with STEMI (72 men, age 58+/-13) who had undergone primary PCI. The decision to administer abciximab immediately prior to PCI was left to the discretion of the operator. Blood samples for analysis of MPs were obtained from the femoral artery before and after PCI. MPs with procoagulant potential were measured using a commercial kit. The cellular origins of MPs were determined by antigenic capture with specific antibodies. RESULTS: Procoagulant MPs captured onto annexin V were not changed significantly after PCI {13.4+/-13.2 nM vs. 13.2+/-16.1 nM phosphatidylserine equivalent (PS eq), p=0.479}. Abciximab was used in 30 of 86 patients (35%) immediately prior to PCI. In patients who had undergone PCI without abciximab, no significant change in the level of MPs was observed after PCI. However, in the abciximab group, the level of circulating MPs was significantly decreased after PCI (12.0+/-10.7 nM vs. 7.8+/-11.7 nM PS eq, p=0.018). Levels of endothelial- and platelet-derived MPs also showed a significant reduction after PCI in the abciximab group. CONCLUSION: Primary PCI with additional abciximab significantly reduced the level of procoagulant MPs regardless of their cellular origins in patients with STEMI.
